Compare Abeona Therapeutics Inc (ABEO) vs Five9 Inc (FIVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Five9 Inc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Five9 Inc trades at $24.09 (market cap $1.91B). The key difference: Five9 Inc is far larger — about 5.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Five9 Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | FIVN | |
|---|---|---|
Market Cap | $373.32M | $1.91B |
Sector | Health | Technology |
52-Week High | $7.23 | $29.16 |
52-Week Low | $4.17 | $13.61 |
Enterprise Value | $228.22M | $1.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Five9 (FIVN) trades at $24.99, up 6.59% today, showing strong momentum after consistently beating earnings estimates. The stock maintains bullish technical signals with moving averages supporting upward trends, though RSI levels indicate potential overbought conditions. Revenue growth has accelerated from $779M in 2022 to $1.15B in 2025, with the company achieving profitability for the first time in 2025 with $39M net income. Recent leadership appointments and AI product launches signal continued innovation in the CX platform space.
The outlook remains positive with 61% analyst buy ratings and a $27 consensus target offering 8% upside. Key catalysts include sustained revenue growth and margin expansion, while risks involve ongoing fiduciary investigations and competitive pressures in the cloud contact center market. The stock's premium valuation (P/E 37.1) requires continued execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
